Lizhu Group announced on December 25. Recently, the holding subsidiary Zhuhai Lizhudan Antibiotic Technology Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the domestically produced drug registration and marketing license application for the “leconchitazumab injection” jointly developed by Lizhumab and Beijing Xinkanghe Biomedical Technology Co., Ltd. was accepted by the State Drug Administration. Leconchitazumab injection is intended for use in adult patients with moderate to severe plaque psoriasis receiving systematic treatment or light therapy.

Lizhu Group announced on December 25. Recently, the holding subsidiary Zhuhai Lizhudan Antibiotic Technology Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the domestically produced drug registration and marketing license application for the “leconchitazumab injection” jointly developed by Lizhumab and Beijing Xinkanghe Biomedical Technology Co., Ltd. was accepted by the State Drug Administration. Leconchitazumab injection is intended for use in adult patients with moderate to severe plaque psoriasis receiving systematic treatment or light therapy.